搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
Pharmaceutical Technology
1 天
Liraglutide by Novo Nordisk for Obesity: Likelihood of Approval
Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...
Too Old to Operate
1 天
Understanding the Link Between Obesity & T2D: Insights & Strategies for Clinicians
By leveraging insights and tools, healthcare professionals can better address the intertwined challenges of obesity and T2D, ...
Healthline
8 天
Managing Type 2 Diabetes and Hormonal Imbalance
Many people with type 2 diabetes can manage their blood sugar levels with lifestyle changes, including exercise and nutrition ...
Verywell Health on MSN
12 天
18 Natural and Medicinal Ways to Balance Hormones
There are several things you can do to help balance your hormones, including diet and lifestyle adjustments and medications.
13 天
on MSN
Semaglutide: a game-changer in the fight against obesity
Semaglutide and similar medications could be key players in bending the curve but enduring change ultimately hinges on a ...
1 天
Beyond obesity: How weight loss drugs lowered heart disease, kidney and liver disease in ...
Eli Lilly and Novo Nordisk are likely to introduce its popular injectable drugs semaglutide and tirzepatide in India in 2025.
News Medical on MSN
9 天
Insulin degradation uncovered as a new driver of resistance
Researchers reveal insulin resistance may be driven by insulin degradation during transit in the bloodstream, challenging the ...
Medpage Today on MSN
15 小时
Sotagliflozin Rejected for T1D; Thyroid and COVID; Diabetes Drug Price Cut
The FDA rejected sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control in adults with type 1 ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈